Evidence map›Paper›PMID 34729144›Full record

ArticleTherapeutic advances in chronic disease2021

Cost-effectiveness of telemedicine care for patients with uncontrolled type 2 diabetes mellitus during the COVID-19 pandemic in Saudi Arabia.

Manal Faleh AlMutairi, Ayla M Tourkmani, Alian A Alrasheedy, Turki J ALHarbi, Abdulaziz M Bin Rsheed, Mohammed ALjehani, Yazed AlRuthia

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in chronic disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Economic Evaluation of Pharmacist-Led Digital Health Interventions: A Systematic Review.International journal of environmental research and public health · 2022
    Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Telemedicine and diabetes during the COVID-19 era.Archives of medical sciences. Atherosclerotic diseases · 2022
    Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Manal Faleh AlMutairiChronic Illness Center, Family and Community Medicine Department, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
Ayla M TourkmaniChronic Illness Center, Family and Community Medicine Department, Prince Sultan Military Medical City, Riyadh 11159, Saudi Arabia.
Alian A AlrasheedyDepartment of Pharmacy Practice, College of Pharmacy, Qassim University, Buraidah 51452, Saudi Arabia.ORCID https://orcid.org/0000-0003-3617-7425
Turki J ALHarbiChronic Illness Center, Family and Community Medicine Department, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
Abdulaziz M Bin RsheedChronic Illness Center, Family and Community Medicine Department, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
Mohammed ALjehaniChronic Illness Center, Family and Community Medicine Department, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
Yazed AlRuthiaDepartment of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia. Pharmacoeconomics Research Unit, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimTelemedicine could be used to provide diabetes care with positive clinical outcomes. Consequently, this study evaluated the cost-effectiveness of telemedicine for patients with uncontrolled type 2 diabetes mellitus (i.e. HbA1c >9). PATIENTS AND

methodsThis was a retrospective chart review of patients with uncontrolled type 2 diabetes attending an outpatient integrated care clinic. The study consisted of two arms, namely a telemedicine care model and a traditional care model with 100 patients in each. The clinical effectiveness (i.e. reduction in HbA1c) and the total cost in both arms were determined, and the incremental cost-effectiveness ratio was calculated. This study adopted propensity score matching.

resultsThe patients in the telemedicine care model had a mean reduction in their HbA1c level of 1.82 (95% CI = 1.56-2.09,

conclusionTelemedicine care is cost-effective in managing type 2 patients with poorly controlled diabetes. Consequently, we believe that telemedicine care can be further expanded and incorporated into routine diabetes care.

Indexed as

cost-effectivenessCOVID-19glycemic controlSaudi Arabiatelemedicinetype 2 diabetes

Identifiers

PMID34729144
PMCPMC8442482

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.